WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Norwegian Cruise Line, Wix.com rise; Cushman & Wakefield, Target fall, Monday, 5/20/2024
Duane Eddy, twangy guitar hero of early rock, dead at age 86
Twins center fielder Byron Buxton leaves game against White Sox with sore right knee
Asian American, Pacific Islander consumers want better brand representation, Nielsen reports
‘The Blue Angels,’ filmed for IMAX, puts viewers in the ‘box’ with the elite flying squad
Hollywood star Bill Murray rides the subway with fellow Cubs fans after watching Chicago's 3
George W. Bush's portraits of veterans are heading to Disney World
Tom Cruise 'hires hawks' to prevent pigeon chaos during Mission Impossible 8 filming in London
National Television Awards 2024 nominations: Michelle Keegan and Leo Woodall go head
Workers rule the streets on May Day
'Constantly learning' Imanaga off to impressive start with the Chicago Cubs
Adames homers twice with 4 RBIs, Brewers beat Rays 7